Contact Us for our BEST PRICE Now! +44 843 557 6440 Email Us Request a Sample
Follow RSS for latest reports on this topicXARELTO (Rivaroxaban) - Market Research and Reports
- XARELTO® is the first and only oral, selective Factor Xa inhibitor with a demonstrated safety profile in multiple indications approved by the FDA.
- XARELTO® is a prescription medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how XARELTO® and warfarin compare in reducing the risk of stroke.
- XARELTO® is also a prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again.
- XARELTO® is also a prescription medicine used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.
Source: http://www.xarelto-us.com/
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
Related Reports:
We found 13 reports that matched your search.
Refine your search, and find more matches, using the form above.
Global Rivaroxaban Industry Market Analysis & Forecast 2018-2023 [Report Updated: 08-03-2018]
In the Global Rivaroxaban Industry Market Analysis & Forecast 2018-2023, the revenue is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023. The production is estimated at XX million in 2017 and is forecasted to reach XX million by the end of 2023, growing at a CAGR of XX% between 2018 and 2023.It covers Region...Read More >>>
Published:
2018-03-08
Published by: S&P Consulting
Prices Starting From:
$3800
Xarelto - API Insight,2018 [Report Updated: 14-02-2018]
IntroductionDelveInsight's, “Xarelto - API Insight, 2018” report provides product and API manufacturers’ details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Xarelto . The report also highlights the patent details of Xarelto . MethodologyThe report is built using data and information sourced from pr...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$500
Xarelto- Drug Insight, 2018 [Report Updated: 14-02-2018]
IntroductionDelveInsight's pharmaceuticals report, Xarelto Drug Insight, 2018 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Xarelto covering the historical global sales and also provides the Xarelto sales estimation during the forecasted period (2018-2020). The report a...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$1000
Global Rivaroxaban Market Research Report Forecast 2017 to 2022 [Report Updated: 23-10-2017]
Delivery of the Report will take 2-3 working days once order is placed.The Global Rivaroxaban Market Research Report Forecast 2017-2022 is a valuable source of insightful data for business strategists. It provides the Rivaroxaban industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate des...Read More >>>
Published:
2017-10-23
Published by: S&P Consulting
Prices Starting From:
$2800
Xarelto - API Insights, 2017 [Report Updated: 10-07-2017]
DelveInsight’s, Xarelto - API Insights, 2017 report provides product and API manufacturers details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to the Xarelto. The report also highlights the patent details of Xarelto. The report is built using data and information sourced from proprietary databases, primary...Read More >>>
Published:
2017-07-10
Published by: Delve Insight
Prices Starting From:
$500
Xarelto- Drug Insights, 2017 [Report Updated: 10-07-2017]
DelveInsight’s pharmaceuticals report, “ Xarelto Drug Insights, 2017” highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Xarelto covering the historical global sales and also provides the Xarelto sales estimation during the forecasted period (2017-2019). The report also...Read More >>>
Published:
2017-07-10
Published by: Delve Insight
Prices Starting From:
$1000
Global and Chinese Rivaroxaban Industry, 2017 Market Research Report [Report Updated: 21-06-2017]
The 'Global and Chinese Rivaroxaban Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Rivaroxaban industry with a focus on the Chinese market. The report provides key statistics on the market status of the Rivaroxaban manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the ind...Read More >>>
Published:
2017-06-21
Published by: Prof Research
Prices Starting From:
$3000
Global Xarelto Market Research Report Forecast 2017 to 2021 [Report Updated: 28-04-2017]
The Global Xarelto Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Xarelto industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Xarelto market stu...Read More >>>
Published:
2017-04-28
Published by: S&P Consulting
Prices Starting From:
$2800
Global Rivaroxaban Market Research Report Forecast 2017 to 2021 [Report Updated: 28-04-2017]
The Global Rivaroxaban Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Rivaroxaban industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Rivaroxaba...Read More >>>
Published:
2017-04-28
Published by: S&P Consulting
Prices Starting From:
$2800
Venous Thromboembolism Treatment Market: By Type (Deep Venous Thrombosis, and Pulmonary Embolism); By Treatment (Heparin, Apixaban, Dabigatran, Rivaroxaban, Edaxaban, Others) & By Region (Europe, North America, Asia-Pacific, RoW)-Forecast (2016-2022) [Report Updated: 27-09-2016]
Venous Thromboembolism (VTE) is a lethal disorder that affects the hospitalized and non-hospitalized patients, recurs frequently, and results in long-term complications including chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). It includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Globally, development of efficient and advanced technol...Read More >>>
Published:
2016-09-27
Published by: Industry ARC
Prices Starting From:
$5250
Peripheral Arterial Disease Market: By Drugs (Cholesterol-, High Blood Pressure, Others Drugs), By Devices (Peripheral Vascular Stents, PTA Guidewires, Others), By Pipeline (Rivaroxaban, DLBS1033, Others) & By Region-Forecast (2016-2021) [Report Updated: 03-02-2016]
Peripheral arterial disease, in which the arteries, other than supplying blood to heart and brain narrow down. Globally, increasing adoption rates of minimally invasive surgeries, and higher healthcare expenditure, rise in the awareness and improving government initiative, and growing population of peripheral arterial disease patient are the prime growth drivers of global peripheral arterial dise...Read More >>>
Published:
2016-02-03
Published by: Industry ARC
Prices Starting From:
$5250
Physician Views: Can Bayer deliver on its Xarelto bullishness?
Scope Last week, FirstWord identified Bayer and Johnson & Johnson's anticoagulant Xarelto as the industry's leading product-level sales growth driver in 2013. Furthermore, in announcing its Q4 results, Bayer increased its own peak revenue forecast for the drug, from around .7 billion to approximately billion.Xarelto has defied commercial expectations, particularly regarding how it has fended ...Read More >>>
Published:
2014-03-10
Published by: FirstWord Pharma
Prices Starting From:
$695
Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?
ScopeSales forecasts for Bristol-Myers Squibb and Pfizer's anticoagulant product Eliquis have declined notably in recent months. According to Bloomberg, current consensus estimates suggest 2018 global revenues of .3 billion. This compares to a previous estimate of .8 billion as recently as April and expectations of over billion last year prior to the drug gaining full regulatory approval. O...Read More >>>
Published:
2013-09-01
Published by: FirstWord Pharma
Prices Starting From:
$695
Additional Searches
You may also like to search separately for: XARELTO (Rivaroxaban)